FEATURE ARTICLES
With less drugs approved in 2025, it is interesting to see what drugs made it through and if any categories of treatment emerged.
- A Deeper Look At Pharma's Structural Supply Chain Vulnerability
- Top 7 AI Lessons Learned
- An AI Use Case in Pharma Process Optimization
- Reimagining HACCP And Other Process Flow Risk Analysis Methods Using Relational Risk Analysis
- November 2025 — CDMO Opportunities And Threats Report
- What 2025 FDA Warning Letters Tell Us About GMP Compliance
- Unpacking The EU's Mutual Recognition Agreements For Pharma
PHARMA ONLINE WHITE PAPERS
-
![Outsourcing Business Human Resources--GettyImages-1305829382]( "Enabling CDMOs To Focus On Core Priorities")
Enabling CDMOs To Focus On Core PrioritiesExplore innovative solutions for CDMO's striving to remain competitive as the biopharmaceutical market grows and evolves.
-
White Paper: Characterization Of Spray Dried Biologics5/7/2025
Discover how spray drying can transform the formulation of complex biologics by improving stability, delivery, and functionality, with insights into the critical techniques and strategies needed for successful development.
-
Accelerating The Development And Production Of High-Quality bsAbs3/7/2024
Bispecific antibodies (bsAbs) are revolutionizing medicine by targeting two disease mechanisms simultaneously. Learn about an innovative platform offering excellent pairing and enhanced productivity.
-
Pharmaceutical Spray Drying – Technology And Applications1/21/2025
Explore the transformative potential of pharmaceutical spray drying in improving drug formulation, bioavailability, and delivery through versatile and innovative applications.
-
Nitrosamine Analysis: Solutions For Risk Management And Analytical Testing8/22/2024
Testing for nitrosamines is essential in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and drug products to ensure safety and compliance.
-
Considerations For Developing The Recirculation/Perfusion Process6/6/2024
Learn about the recirculation and perfusion processes made possible by single-use, fixed-bed bioreactors designed for scaling up adherent cell culture processes.
PHARMA ONLINE APP NOTES & CASE STUDIES
NEWSLETTER ARCHIVE
- 01.15.26 -- An AI Use Case In Pharma Process Optimization
- 01.15.26 -- STREAM Edition: Balancing GLP-1 Quality With Demand
- 01.13.26 -- Leveraging Historical Data To Accelerate Process Understanding
- 01.10.26 -- Pharmaceutical Online Best Of December
- 01.10.26 -- Packaging And Inspection Product Showcase
INDUSTRY NEWS
-
![FDA Logo on phone screen-GettyImages-2208861549]( "Høeg In, Pazdur Out At The FDA")
Høeg In, Pazdur Out At The FDAWhat an eventful week it has been at the FDA, with Richard Pazdur, M.D., resigning after weeks in his position as director of Center for Drug Research and Evaluation (CDER), and his vacancy being quickly filled by acting director Tracy Beth Høeg, M.D.
-
![business peope negotiating-GettyImages-637902194]( "9 Drugs Granted Fast Track By FDA's Voucher Program")
9 Drugs Granted Fast Track By FDA's Voucher ProgramWith targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.
-
![Pharmaceutical sorting machine, pills-GettyImages-1499814881]( "Leaders In The Excipient Market: Region And Type")
Leaders In The Excipient Market: Region And TypeThough North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.
-
![GettyImages-2189405678-GLP-1-obesity]( "Pfizer Strengthens Obesity Foothold With Metsera Acquisition")
Pfizer Strengthens Obesity Foothold With Metsera AcquisitionAfter discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.
-
![weight loss, diabetes, insulin pen-GettyImages-2196049931]( "FDA Cracks Down On GLP-1 Imports")
FDA Cracks Down On GLP-1 ImportsGLP-1 bulk drug substances must be detained without physical examination (DWPE) unless they are on a list (Green List) of approved foreign GLP-1 manufacturers.
PHARMACEUTICAL ONLINE CONTENT COLLECTIONS
Explore how sterility assurance, including sterilization validation and environmental monitoring, is essential for controlling microbial contamination in mammalian cell production to ensure patient safety. Check out the latest e-book from Pharmaceutical Online.
More Content CollectionsSUPPLIER NEWS
-
Wilmington PharmaTech Appoints Seasoned Commercial Leader To Drive Growth1/16/2026
Wilmington PharmaTech (“WPT”), a U.S.-based specialty contract research, development and manufacturing organization (CRDMO) focused on complex custom small molecule API, today announced that it has appointed Mike Shearer to the role of Chief Commercial Officer, where he will play a pivotal role in driving growth, strengthening client partnerships, and furthering the organization’s position as a trusted partner for API development and manufacturing. Shearer will report to Hui-Yin “Harry” Li, Ph.D., WPT’s Founder and CEO.
-
Coating Place Secures Growth Capital Investment By 1315 Capital1/16/2026
Coating Place, a leading U.S.-based contract development and manufacturing organization (CDMO), has secured a strategic, growth investment from 1315 Capital, a Philadelphia-based healthcare-focused private equity firm.
-
INTERPHEX Opens Registration For 2026 With Expanded Show Floor, Education And Debut Of New Contract & Outsourcing Hub1/14/2026
INTERPHEX, the premier pharmaceutical and biotechnology event returns to NYC, taking place April 21 – 23 at the Javits Center. Representing the full scope of the pharmaceutical value chain, INTERPHEX continues to be the event to discover breakthrough solutions that enhance manufacturing, development, regulatory compliance and supply chain efficiency to support the evolving industry.
-
AbbVie To Buy Device Manufacturing Facility From West Pharmaceutical Services1/14/2026
The acquisition of the Tempe, Arizona facility will expand U.S.-based drug delivery device capacity and support the company’s $10 billion manufacturing investment.
-
Johnson & Johnson Announces Plans For New Manufacturing Facilities In North Carolina And Pennsylvania1/13/2026
Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs.
